<p>/PRNewswire/ -- <strong>Kazia Therapeutics Limited (NASDAQ: KZIA)</strong> 是一家专注于肿瘤学的药物开发公司，今天宣布已与一些知名的机构和合格投资者签署了一项证券购买协议，以进行私募股权融资（PIPE）。根据证券购买协议，公司同意向投资者提供和出售总计约 5000 万美元的普通股和预先融资的认股权证，每股的购买价格相当于每个美国存托股票（ADS）5.00 美元，每个 ADS 代表 500 股普通股。该 PIPE 融资结构为简单的股权投资，没有普通认股权证的覆盖。PIPE 融资由专注于医疗保健的投资者主导，包括 Adar1 Capital Management LLC、Ikarian Capital LLC、Stonepine Capital Management、Velan Capital Investment Management LP 和 Revach Capital Management, LLC，以及现有股东 Jorey Chernett。该交易预计将在 2025 年 12 月 3 日星期三完成，具体取决于惯例的交割条件。</p>
<p>Konik Capital Partners, LLC 作为该 PIPE 的独家配售代理。</p>
<p>预计公司从 PIPE 中获得的净收益约为 4650 万美元，扣除配售代理费用和公司需支付的其他估计发行费用。公司目前打算将此次发行的净收益与现有现金、现金等价物和可交易证券结合使用，以支持其主要项目 paxalisib 的持续临床开发，该药物是一种能够穿透大脑的双重 PI3K/mTOR 抑制剂，目前正在进行针对脑癌和晚期乳腺癌的临床试验，推进 PD-L1 降解剂项目，以及用于一般企业用途。公司预计，PIPE 的净收益与现有现金和现金等价物结合，将使其现金储备延续到 2028 年下半年。</p>
<p>在此次 PIPE 中出售的证券是在不涉及公开发行的交易中进行的，未根据《1933 年证券法》及其修订版或适用的州证券法进行注册，且在没有有效注册声明或适用的注册豁免的情况下，可能无法在美国提供或出售。根据证券购买协议，公司已同意在交割后 30 天内向美国证券交易委员会（SEC）提交一份货架注册声明，以注册代表普通股的 ADS 及其下方的预融资认股权证的转售。</p>
<p>本新闻稿不构成出售证券的要约或购买证券的邀请，也不应在任何州或司法管辖区进行这些证券的销售，除非在该州或司法管辖区的证券法下注册或合格之前。根据转售注册声明的任何证券发行将仅通过招股说明书进行。</p>
<p><strong>关于 Kazia Therapeutics Limited</strong></p>
<p>Kazia Therapeutics Limited (NASDAQ: <strong>KZIA</strong>) 是一家创新的肿瘤学药物开发公司，总部位于澳大利亚悉尼。我们的主要项目是 paxalisib，一种能够穿透大脑的全 PI3K/mTOR 抑制剂，正在开发用于治疗多种形式的脑癌，包括胶质母细胞瘤和脑转移。Phase 1b 临床试验也在进行中，评估 paxalisib 与检查点抑制剂和化疗联合使用，针对晚期三阴性乳腺癌患者。EVT801，一种选择性 VEGFR3 抑制剂，目前正在进行针对晚期实体瘤的 Phase 1 临床试验。Kazia 正在努力快速推进这些资产的临床开发并走向商业化。</p>
<p><strong>前瞻性声明</strong></p>
<p>本公告可能包含前瞻性声明，符合 1995 年《私人证券诉讼改革法》的定义，这些声明通常可以通过使用 “可能”、“将”、“估计”、“未来”、“前瞻”、“预期” 或其他类似词语来识别。任何描述 Kazia 未来计划、战略、意图、期望、目标、目标或前景的声明，以及其他非历史事实的声明，也都是前瞻性声明，包括但不限于关于：PIPE 的完成、相关的惯例交割条件的满足、PIPE 收益的预期用途、PIPE 完成后公司现金储备延续到 2028 年下半年的预期，以及公司的未来期望、计划和前景。这些声明基于 Kazia 对未来事件和影响其业务的未来趋势的当前期望和预测，并受到某些风险和不确定性的影响，这些风险和不确定性可能导致实际结果与前瞻性声明中预期的结果有重大差异，包括与市场和其他条件相关的风险、与临床和前临床试验及产品开发相关的风险，包括初步或中期数据可能不反映最终结果的风险、与监管批准相关的风险，以及与全球经济状况的影响相关的风险。这些及其他风险和不确定性在 Kazia 最近提交给 SEC 的 20-F 表格年度报告中有更详细的描述，以及在随后的 SEC 文件中。Kazia 没有义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非法律要求。投资者不应对这些前瞻性声明过于依赖，这些声明仅适用于本公告的日期。</p>
<p><strong>如需进一步信息，请联系：</strong></p>
<p>Alex Star</p>
<p>董事总经理</p>
<p>LifeSci Advisors LLC</p>
<p>Astarr@lifesciadvisors.com</p>
<p>电话：+1 (201) 786-8795</p>
<p>来源：Kazia Therapeutics Limited</p>

KZIA

<p>Kazia Therapeutics 宣布与机构投资者进行 5000 万美元的私募股权融资，由专注于医疗保健的公司主导。融资所得将支持其主要项目 paxalisib 的临床开发，并将现金流延续至 2028 年。该交易预计将于 2025 年 12 月 3 日完成，具体需满足相关条件。这些证券未在证券法下注册，转售时需要进行货架注册声明</p>

<p>, /PRNewswire/ -- <strong>Kazia Therapeutics Limited (NASDAQ: KZIA)</strong>, an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and accredited investors for a private placement of equity securities (PIPE). Pursuant to the securities purchase agreement, the Company agreed to offer and sell to the investors an aggregate of approximately $50.0 million of ordinary shares and prefunded warrants, at a purchase price per share that is the equivalent of $5.00 per ADS, each ADS representing 500 ordinary shares. The PIPE is structured as a straightforward equity investment with no common warrant coverage. The PIPE financing was led by healthcare-dedicated investors including Adar1 Capital Management LLC, Ikarian Capital LLC, Stonepine Capital Management, Velan Capital Investment Management LP, and Revach Capital Management, LLC, alongside existing shareholders, including Jorey Chernett. The transaction is expected to close on Wednesday, December 3, 2025, subject to customary closing conditions.</p>
<div class="lb-trans"><p>/PRNewswire/ -- <strong>Kazia Therapeutics Limited (NASDAQ: KZIA)</strong> 是一家专注于肿瘤学的药物开发公司，今天宣布已与一些知名的机构和合格投资者签署了一项证券购买协议，以进行私募股权融资（PIPE）。根据证券购买协议，公司同意向投资者提供和出售总计约 5000 万美元的普通股和预先融资的认股权证，每股的购买价格相当于每个美国存托股票（ADS）5.00 美元，每个 ADS 代表 500 股普通股。该 PIPE 融资结构为简单的股权投资，没有普通认股权证的覆盖。PIPE 融资由专注于医疗保健的投资者主导，包括 Adar1 Capital Management LLC、Ikarian Capital LLC、Stonepine Capital Management、Velan Capital Investment Management LP 和 Revach Capital Management, LLC，以及现有股东 Jorey Chernett。该交易预计将在 2025 年 12 月 3 日星期三完成，具体取决于惯例的交割条件。</p>
</div><p>Konik Capital Partners, LLC is acting as the exclusive placement agent for the PIPE.</p>
<div class="lb-trans"><p>Konik Capital Partners, LLC 作为该 PIPE 的独家配售代理。</p>
</div><p>The net proceeds to the Company from the PIPE are expected to be approximately $46.5million, after deducting placement agent's fees and other estimated offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to support the continued clinical development of its lead program paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor currently in clinical trials for both brain cancer and advanced breast cancer, advancing the PD-L1 degrader program, and for general corporate purposes. The Company expects the net proceeds from the PIPE, combined with the existing cash and cash equivalents, will extend its cash runway into the second half of 2028.</p>
<div class="lb-trans"><p>预计公司从 PIPE 中获得的净收益约为 4650 万美元，扣除配售代理费用和公司需支付的其他估计发行费用。公司目前打算将此次发行的净收益与现有现金、现金等价物和可交易证券结合使用，以支持其主要项目 paxalisib 的持续临床开发，该药物是一种能够穿透大脑的双重 PI3K/mTOR 抑制剂，目前正在进行针对脑癌和晚期乳腺癌的临床试验，推进 PD-L1 降解剂项目，以及用于一般企业用途。公司预计，PIPE 的净收益与现有现金和现金等价物结合，将使其现金储备延续到 2028 年下半年。</p>
</div><p>The securities sold in this PIPE are being made in a transaction not involving a public offeringand have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold inthe United Statesabsent an effective registration statement or an applicable exemption from registration requirements. Pursuant to the securities purchase agreement, the Company has agreed to file a shelf registration statement with the U.S. Securities and Exchange Commission (SEC) within 30 days of the closing to register the resale of ADSs representing the ordinary shares and those underlying the pre-funded warrants.</p>
<div class="lb-trans"><p>在此次 PIPE 中出售的证券是在不涉及公开发行的交易中进行的，未根据《1933 年证券法》及其修订版或适用的州证券法进行注册，且在没有有效注册声明或适用的注册豁免的情况下，可能无法在美国提供或出售。根据证券购买协议，公司已同意在交割后 30 天内向美国证券交易委员会（SEC）提交一份货架注册声明，以注册代表普通股的 ADS 及其下方的预融资认股权证的转售。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering of the securities described above under the resale registration statement will only be by means of a prospectus.</p>
<div class="lb-trans"><p>本新闻稿不构成出售证券的要约或购买证券的邀请，也不应在任何州或司法管辖区进行这些证券的销售，除非在该州或司法管辖区的证券法下注册或合格之前。根据转售注册声明的任何证券发行将仅通过招股说明书进行。</p>
</div><p><strong>About Kazia Therapeutics Limited</strong></p>
<div class="lb-trans"><p><strong>关于 Kazia Therapeutics Limited</strong></p>
</div><p>Kazia Therapeutics Limited (NASDAQ: <strong>KZIA</strong>) is an innovative oncology-focused drug development company, based inSydney, Australia. Our lead program is paxalisib, a brain-penetrant pan-PI3K/mTOR inhibitor, which is being developed to treat multiple forms of brain cancer, including glioblastoma and brain metastases. A Phase1bclinical trial is also underway evaluating paxalisib in combination with checkpoint inhibition and chemotherapy for patients with advanced triple-negative breast cancer. EVT801, a selective VEGFR3 inhibitor, is currently in a Phase 1 clinical trial for advanced solid tumors. Kazia is working to rapidly progress these assets through clinical development and toward commercialization.</p>
<div class="lb-trans"><p>Kazia Therapeutics Limited (NASDAQ: <strong>KZIA</strong>) 是一家创新的肿瘤学药物开发公司，总部位于澳大利亚悉尼。我们的主要项目是 paxalisib，一种能够穿透大脑的全 PI3K/mTOR 抑制剂，正在开发用于治疗多种形式的脑癌，包括胶质母细胞瘤和脑转移。Phase 1b 临床试验也在进行中，评估 paxalisib 与检查点抑制剂和化疗联合使用，针对晚期三阴性乳腺癌患者。EVT801，一种选择性 VEGFR3 抑制剂，目前正在进行针对晚期实体瘤的 Phase 1 临床试验。Kazia 正在努力快速推进这些资产的临床开发并走向商业化。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This announcement may contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by the use of words such as &#34;may,&#34; &#34;will,&#34; &#34;estimate,&#34; &#34;future,&#34; &#34;forward,&#34; &#34;anticipate,&#34; or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the completion of the PIPE, the satisfaction of customary closing conditions related thereto, the intended use of proceeds from the PIPE, the anticipated extension of the Company's cash runway into the second half of 2028 following completion of the PIPE, and the Company's future expectations, plans and prospects. Such statements are based on Kazia's current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: related to market and other conditions, associated with clinical and preclinical trials and product development, including the risk that preliminary or interim data may not reflect final results, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia's most recent Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. Investors should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.</p>
<div class="lb-trans"><p>本公告可能包含前瞻性声明，符合 1995 年《私人证券诉讼改革法》的定义，这些声明通常可以通过使用 “可能”、“将”、“估计”、“未来”、“前瞻”、“预期” 或其他类似词语来识别。任何描述 Kazia 未来计划、战略、意图、期望、目标、目标或前景的声明，以及其他非历史事实的声明，也都是前瞻性声明，包括但不限于关于：PIPE 的完成、相关的惯例交割条件的满足、PIPE 收益的预期用途、PIPE 完成后公司现金储备延续到 2028 年下半年的预期，以及公司的未来期望、计划和前景。这些声明基于 Kazia 对未来事件和影响其业务的未来趋势的当前期望和预测，并受到某些风险和不确定性的影响，这些风险和不确定性可能导致实际结果与前瞻性声明中预期的结果有重大差异，包括与市场和其他条件相关的风险、与临床和前临床试验及产品开发相关的风险，包括初步或中期数据可能不反映最终结果的风险、与监管批准相关的风险，以及与全球经济状况的影响相关的风险。这些及其他风险和不确定性在 Kazia 最近提交给 SEC 的 20-F 表格年度报告中有更详细的描述，以及在随后的 SEC 文件中。Kazia 没有义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非法律要求。投资者不应对这些前瞻性声明过于依赖，这些声明仅适用于本公告的日期。</p>
</div><p><strong>For further information contact:</strong></p>
<div class="lb-trans"><p><strong>如需进一步信息，请联系：</strong></p>
</div><p>Alex Star</p>
<div class="lb-trans"><p>Alex Star</p>
</div><p>Managing Director</p>
<div class="lb-trans"><p>董事总经理</p>
</div><p>LifeSci Advisors LLC</p>
<div class="lb-trans"><p>LifeSci Advisors LLC</p>
</div><p>Astarr@lifesciadvisors.com</p>
<div class="lb-trans"><p>Astarr@lifesciadvisors.com</p>
</div><p>Ph: +1 (201) 786-8795</p>
<div class="lb-trans"><p>电话：+1 (201) 786-8795</p>
</div><p>SOURCE Kazia Therapeutics Limited</p>
<div class="lb-trans"><p>来源：Kazia Therapeutics Limited</p>
</div>

Kazia Therapeutics 宣布 5000 万美元股权证券私募的定价 | KZIA 股票新闻